- Home
- AUTL
as 11-14-2025 3:44pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 368.6M | IPO Year: | 2018 |
| Target Price: | $9.12 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $3.45 | Next Earning Date: | 11-12-2025 |
| Revenue: | $51,128,000 | Revenue Growth: | 406.67% |
| Revenue Growth (this year): | 643.5% | Revenue Growth (next year): | 108.69% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
How Investors Are Reacting To Autolus Therapeutics (AUTL) Trimming Losses and Appointing a New Finance Chief
GlobeNewswire
3 days ago
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
MT Newswires
3 days ago
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading
GuruFocus.com
4 days ago
Autolus Therapeutics PLC (AUTL) Q3 2025 Earnings Call Highlights: Navigating Challenges and ...
Simply Wall St.
4 days ago
November 2025's Promising Penny Stocks To Watch
MT Newswires
4 days ago
European Equities Traded in the US as American Depositary Receipts Rise Wednesday
GlobeNewswire
4 days ago
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.